Rajiv De Silva
Rajiv De Silva is President, Chief Executive Officer and a Director of Endo. Prior to joining Endo in March 2013, Mr. De Silva served as the President of Valeant Pharmaceuticals International, Inc. from October 2010 to January 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from January 2009 until January 2013. He was responsible for all specialty pharmaceutical operations, including sales and marketing, research and development, manufacturing and business development. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia/New Zealand. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. During this time, he played a key leadership role at Novartis' Vaccines & Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Principal at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. and is currently a Member of the Board of Trustees at Kent Place School in Summit, NJ. He holds a Bachelor of Science in Engineering, Honors from Princeton University, and a Master of Science from Stanford University and a Master of Business Administration with Distinction from the Wharton School at the University of Pennsylvania.
Robert J. Cobuzzi Jr., Ph.D.
Robert J. Cobuzzi Jr. is Senior Vice President, Corporate Development of Endo. Dr. Cobuzzi joined Endo in 2005. Before joining Endo, he held management positions in clinical development and licensing at Adolor Corporation. Prior to Adolor, Dr. Cobuzzi gained extensive experience in global regulatory affairs and biologics at Centocor/Johnson & Johnson, and in clinical development at AstraMerck in the areas of thrombosis and hypertension. Dr. Cobuzzi received his Ph.D. in molecular and cellular biochemistry from Loyola University Chicago, and a Bachelor of Arts degree with majors in biochemistry and art history from Colby College. He completed a post-doctoral fellowship in the Department of Experimental Therapeutics at Roswell Park Cancer Institute. He serves as a member of Sunstone Capital’s Business Development Advisory Board, and as a member of the U.S. Department of Commerce and the Office of the U.S. Trade Representative’s Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health/Science Products and Services (ITAC3).
Larry Cunningham, Executive Vice President, Human Resources, joined Endo Pharmaceuticals in May 2008. In this role he leads all aspects of human resources in enabling the development and growth of Endo. Prior to joining Endo, Mr. Cunningham led Johnson & Johnson’s global recruiting and talent acquisition organization. Mr. Cunningham also has extensive business-based human resources leadership experience. He was Vice President, Human Resources, for DePuy, Inc., a wholly owned subsidiary of Johnson & Johnson, which he joined following the acquisition of Centocor, where he was Vice President, Human Resources. Prior to joining Centocor, Mr. Cunningham gained extensive domestic and international experience in human resources management and organization development at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Corning Clinical Laboratories (now Quest Diagnostics). Mr. Cunningham holds a B.A. in Labor Studies from the Pennsylvania State University and a Master of Science in Business Administration from Temple University.
Blaine Davis, Senior Vice President, Corporate Affairs, joined Endo in 2008. In this role, he leads the company’s investor relations and corporate communications functions as well as provides strategic counsel to the executive team on the development, execution and communication of corporate strategy. Prior to joining Endo, Blaine was Director of Alliance Management within the Corporate & Business Development unit at Bristol-Myers Squibb (BMS). In this role, he was responsible for a key collaboration for two late stage diabetes development programs with AstraZeneca as well as management of other key alliance partners. He joined BMS in January 2005 as Director of Investor Relations. Blaine began his career at Thomson Financial in New York City as Vice President of Capital Markets. He holds a Bachelor of Arts degree in Biology and Economics from Middlebury College, Vermont.
Don DeGolyer, Chief Operating Officer of Pharmaceuticals, joined Endo in August 2013. In this role, he leads both the Qualitest and Endo Pharmaceuticals businesses as fully integrated business units. Prior to joining Endo, Mr. DeGolyer served as President of Sandoz Inc. (a Novartis company) the second largest generics company in the world. While at Novartis, Mr. DeGolyer held various senior leadership positions including, US Managed Markets, Established Medicines for Novartis Pharmaceuticals and was a member of the Executive Committee. Prior to Novartis, Mr. DeGolyer held positions of increasing responsibilities with Johnson and Johnson for 11 years in pharmaceutical commercial roles including senior leadership positions in marketing and sales. Additionally, Mr. DeGolyer has international pharmaceutical experience and health information technology expertise, having held senior leadership roles at Oxford GlycoSciences Plc and ParkStone Medical, respectively. He began his career at Pfizer in sales and sales management. Mr. DeGolyer served as Vice Chairman on the Executive Committee and Board of Directors for the Generic Pharmaceutical Association (GPhA). He holds a Masters of Business Administration from Fairleigh Dickinson University and is a graduate of University of Rochester.
Camille Farhat joined Endo in September 2012 as President of AMS, a world leader in developing and delivering medical devices and procedures to treat patients with pelvic health conditions. Mr. Farhat brings broad global experience from assignments in 10 countries and nine industries over 22 years. He is a business executive with a track record of revitalizing, turning around, and profitably growing businesses. Before joining Endo, Mr. Farhat held the position of General Manager of Baxter Pharmaceuticals & Technologies (BPT). Camille joined Baxter in February 2006 as General Manager of Global Infusion Systems. Prior to Baxter, Mr. Farhat was with Medtronic where he held the position of Vice President of Business Development after he was Global General Manager of Medtronic’s Gastroenterology and Urology division. He spent 13 years with General Electric (GE) where he gained broad executive experience with assignments in many businesses, geographies, and functional areas, leading up to his final role with the company as General Manager for the Computed Tomography (CT) business.
He holds a Master of Business Administration from Harvard University, a degree in European Union Studies from Institut National d’Etudes Politiques de Paris, and a Bachelor of Sciences (summa cum laude) in International Finance and Accounting from Northeastern University.
Ivan Gergel, M.D.
Ivan P. Gergel, M.D., was appointed Executive Vice President, Research & Development and Chief Scientific Officer in April 2008. Prior to joining Endo, Dr. Gergel was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999. Dr. Gergel received his M.D. from the Royal Free Medical School of the University of London and an MBA from the Wharton School. Dr. Gergel is a member of the Board of Directors of Pennsylvania BIO as well as a member of the Board of Directors of the PhRMA Foundation and has served as a Member of PhRMA’s Scientific and Regulatory Executive Committee.
Brian Lortie is Senior Vice President and General Manager of Endo Pharmaceuticals, Endo’s branded pharmaceutical business currently focused in the areas of pain management, urology, and endocrinology. In this role, he leads this fully integrated business with responsibility for all strategic, commercial, and operational functions including sales and marketing, strategy and portfolio development, commercial operations, managed markets, supply chain, and quality. He joined Endo in 2009 from GlaxoSmithKline, having served in a number of executive roles in the US and internationally, including Vice President, External Ventures; Vice President of Marketing, US; Vice President and Global Head, HPV Vaccine Franchise; and Managing Director/General Manager, Ireland. He brings to Endo an extensive track record of leadership success in all areas of the pharmaceutical business including product development, commercialization, business development and strategy. Brian holds a Bachelor of Arts degree with honors in Biology and Psychology from Boston University and studied at the Villanova University Graduate School of Business.
Caroline B. Manogue
Caroline B. Manogue has served as Executive Vice President, Chief Legal Officer and Secretary since 2004. Prior to joining Endo in 2000 as Endo’s Senior Vice President, General Counsel and Secretary, she practiced law in the New York office of the law firm Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers & acquisitions, securities and corporate law. At Endo, she is responsible for all aspects of the company’s legal function, including securities law, litigation, intellectual property and commercial law, as well as overseeing compliance with current laws and existing pharmaceutical company guidelines relating to, among other things, clinical, sales and marketing practices. In her capacity as Secretary, she is responsible for corporate governance matters and reports directly to the Board of Directors. Ms. Manogue received her J.D. from Fordham Law School and her B.A. cum laude from Middlebury College. She was the 2011-2012 Chairperson of the PhRMA Law Section and is a member of the Board of Trustees of the Healthcare Institute of New Jersey (“HINJ”) and a member of HINJ’s Finance and Audit Committee.
Jon Smollen, Executive Vice President and Chief Compliance Officer, joined Endo in August 2011. In this role, he is responsible for the strategic direction and operations of Endo’s corporate compliance program. Mr. Smollen previously was Vice President and Chief Compliance Officer for Siemens Healthcare USA with responsibility for its laboratory diagnostic and diagnostic imaging businesses in the U.S. Prior to Siemens, Mr. Smollen held a number of leadership positions at Wyeth including Vice President, Commercial Excellence and Compliance and Chief Privacy Officer and established several global programs to strategically address existing and emerging industry requirements. Prior to Wyeth, Mr. Smollen was an Attorney Advisor to Federal Trade Commissioner Thomas B. Leary and was in private practice in Washington, D.C. He also served as a federal judicial clerk. He holds a B.A. from Georgetown University, an M.A. in International Relations from Columbia University and a J.D. from the University of Virginia School of Law.
Suketu “Suky” Upadhyay, Executive Vice President and Chief Financial Officer, joined Endo September 2013. Prior to joining Endo, since 2010, Mr. Upadhyay served as Interim Chief Financial Officer as well as Senior Vice President of Finance and Corporate Controller of Becton, Dickinson & Co (BD). In addition to other executive finance roles at BD, from 2007 to 2010, he served in various finance leadership roles at AstraZeneca and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG and received his CPA in May 1996. He received a Bachelor of Science in Finance from Albright College and received a Master of Business Administration from The Fuqua School of Business at Duke University.